Fatal Stevens-Johnson syndrome/toxic epidermal necrolysis induced by allopurinol-rituximab-bendamustine therapy

Journal of Oncology Pharmacy Practice

Volumn 21, Issue 5, 2015, Pages 388-392

  Fallon, Michael J ^a   Heck, Jessica N ^b  

^a University of Wisconsin Health   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

allopurinol; bendamustine; Rituximab; Steven's Johnson syndrome; toxic epidermal necrolysis; tumor lysis syndrome

Indexed keywords

ALLOPURINOL; ANTIBIOTIC AGENT; BENDAMUSTINE; RITUXIMAB; ANTINEOPLASTIC AGENT;

AGED; ANALGESIA; ARTICLE; B CELL LYMPHOMA; BODY SURFACE; CANCER CHEMOTHERAPY; CASE REPORT; CAUCASIAN; DEBRIDEMENT; DRUG USE; FATIGUE; FOOD AND DRUG ADMINISTRATION; HOSPITAL ADMISSION; HUMAN; HYDRATION; KIDNEY FUNCTION; LARGE CELL LYMPHOMA; LUBRICATION; MACROPAPULAR RASH; MALE; MEDICAL HISTORY; MUCOSA; NEUTROPHIL COUNT; NUTRITIONAL SUPPORT; PAPULAR RASH; PRIORITY JOURNAL; SORE THROAT; STEVENS JOHNSON SYNDROME; TACHYCARDIA; THROMBOCYTE COUNT; TOXIC EPIDERMAL NECROLYSIS; TREATMENT DURATION; TUMOR CELL DESTRUCTION; FATALITY; LYMPHOMA, B-CELL; STEVENS-JOHNSON SYNDROME;

AGED; ALLOPURINOL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENDAMUSTINE HYDROCHLORIDE; FATAL OUTCOME; HUMANS; LYMPHOMA, B-CELL; MALE; RITUXIMAB; STEVENS-JOHNSON SYNDROME;

EID: 84940108100     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155214533368     Document Type: Article

References (17)

1. Schwartz RA, McDonohough PH, Lee BW,. Toxic epidermal necrolysis. J Am Acad Dermatol 2013; 69: 187e1-187e16.
2. Gerull R, Nelle M, Schaible T,. Toxic epidermal necrolysis and Stevens-Johnson syndrome: a review. Crit Car Med 2011; 39: 1521-1532.
3. Lambertini M, Del Mastro L, Gardin G,. Stevens-Johnson syndrome after treatment with bendamustine. Leuk Res 2012; 36: 153-154.
4. Alamdari HS, Pinter-Brown L, Cassarino DS,. Severe cutaneous interface drug eruption associated with bendamustine. Dermatol Online J 2010; 16: 11-13.
5. Bashir S, Shah SM, Babar I,. Allopurinol induced Stevens-Johnson syndrome: a case report. J Pak Med Assoc 2000; 50: 207-209.
6. Pennell DJ, Nuan TO, O'Doherty MJ,. Fatal Stevens-Johnson syndrome in a patient on captopril and allopurinol. Lancet 1984; 1: 463-466.
7. Haur YL, Pang SM, Thamotharampillai T,. Allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis. J Am Acad Dermatol 2008; 59: 352-353.
8. Somkrua R, Eickman EE, SaoKaew S,. Association of HLA-B∗5801 allele and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. BMC Med Genet 2011; 12: 118-127.
9. Genentech Inc. Rituxan (package insert). South San Francisco: Genentech Inc, 2013.
10. Lowndes S, Darby A, Mead G,. Stevens-Johnson syndrome after treatment with rituximab. Ann Oncol 2002; 13: 1948-1950.
11. Henning JS, Firoz BF,. Rituxan is not associated with Stevens-Johnson syndrome. Ann Oncol 2011; 22: 1463-1464.
12. Teva Pharmaceuticals Inc. Treanda (package insert). North Wales, PA: Teva Pharmaceuticals Inc, 2013.
13. Robinson K, Williams M, van der Jagt R,. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent b-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008; 26: 4473-4479.
14. Hettiaratchy S, Papini R,. Initial management of a burn: assessment and resuscitation. BMJ 2004; 329: 101-103.
15. Naranjo CA, Busto U, Sellers EM,. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-245.
16. Bastuji-Garin S, Fouchard N, Bertoc M,. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000; 115: 149-153.
17. Garcia-Doval I, LeCleach L, Bocquet H,. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol 2000; 136: 323-327.